Sign in

PBH on NYSE

Prestige Brands

Logo: Prestige Brands Holdings, Inc., Public domain, via Wikimedia Commons6

American company that markets and distributes over-the-counter healthcare

Prestige Consumer Healthcare Inc. (formerly Prestige Brands, Inc.) is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.3 Its shares trade on NYSE under the symbol PBH.1 Wikipedia text CC BY-SA 4.0

$49.38 up 0.97 (2.01%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

$1.1BRevenue, fiscal 20267
$190.3MNet income, fiscal 20267
1996Founded1

Compare with Acadia Pharmaceuticals, Nasus Pharma Ltd or MADRIGAL PHARMACEUTICALS, INC., or pick any stock.

  • TickerPBH on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersTarrytown1
  • Websitewww.prestigebrands.com
  • Legal formDelaware corporation1
  • LEI549300JBVP4J6D42I2354
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O NATIONAL REGISTERED AGENTS, INC., 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 37373624

See how the biggest companies compare on our leaderboards

Prestige Consumer Healthcare Inc. (formerly Prestige Brands, Inc.) is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

54.7%Gross margin7
28.4%Operating margin7
17.5%Net margin7
-4.3%Revenue growth, 20267
10.1%Return on equity7
0.53×Debt to equity7
$246.4MFree cash flow7

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Gastrointestinal brought in 24% of the revenue Prestige Brands broke down this way in fiscal 2026.

  1. Gastrointestinal$259.8M724%up 2% from 2025
  2. Women's Health$227.8M721%down 4% from 2025
  3. Eye and Ear Care$142.9M713%down 22% from 2025
  4. Dermatologicals$125.9M712%down 2% from 2025
  5. Analgesics$113.9M710%down 3% from 2025
  6. Cough and Cold$101.9M79%down 4% from 2025
  7. Oral Care$101.1M79%up 6% from 2025
  8. Other OTC$15.4M71%up 12% from 2025
  9. Product and Service, Other$4.0M70%up 235% from 2025
Products and services by year
Products and services202420252026
Gastrointestinal$231.6M$255.9M$259.8M
Women's Health$240.4M$236.8M$227.8M
Eye and Ear Care$179.4M$183.3M$142.9M
Dermatologicals$129.1M$128.9M$125.9M
Analgesics$117.5M$117.7M$113.9M
Cough and Cold$119.0M$106.2M$101.9M
Oral Care$96.3M$95.0M$101.1M
Other OTC$12.0M$13.8M$15.4M
Product and Service, Other$311.0K$1.2M$4.0M

Business segments

North American OTC Healthcare brought in 84% of the revenue Prestige Brands broke down this way in fiscal 2026.

  1. North American OTC Healthcare$913.6M784%down 5% from 2025
  2. International OTC Healthcare$175.1M716%down 1% from 2025
Business segments by year
Business segments202420252026
North American OTC Healthcare$958.3M$960.0M$913.6M
International OTC Healthcare$167.1M$177.8M$175.1M

Regions

United States brought in 78% of the revenue Prestige Brands broke down this way in fiscal 2026.

  1. United States$850.4M778%down 5% from 2025
  2. Outside the United States$238.3M722%down 1% from 2025
Regions by year
Regions202420252026
United States$886.5M$897.5M$850.4M
Outside the United States$238.9M$240.2M$238.3M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue45¢$493.1M
  • Other costs31¢$338.1M
  • Income tax6¢$67.2M
  • Profit17¢$190.3M

Out of $1.1B in revenue.7

Where each dollar of operating cash went, fiscal 2026

  • Capital spending4¢$11.2M
  • Share buybacks61¢$156.3M
  • Kept or used elsewhere35¢$90.2M

Out of $257.6M of cash from operations.7

Financial statements

Revenue10111213147$1.1B in 2026+12% since 2019
0$500.0M$1.0B$1.5B2019: $975.8M$975.8M20192020: $963.0M$963.0M2020−1%2021: $943.4M$943.4M2021−2%2022: $1.1B$1.1B2022+15%2023: $1.1B$1.1B2023+4%2024: $1.1B$1.1B2024−0%2025: $1.1B$1.1B2025+1%2026: $1.1B$1.1B2026−4%
Gross profit10111213147$595.6M in 2026+7% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $555.6M$555.6M20192020: $552.2M$552.2M2020−1%2021: $547.5M$547.5M2021−1%2022: $620.6M$620.6M2022+13%2023: $625.3M$625.3M2023+1%2024: $624.4M$624.4M2024−0%2025: $634.5M$634.5M2025+2%2026: $595.6M$595.6M2026−6%
Operating income10111213147$309.4M in 2026+358% since 2019
-$100.0M0$100.0M$200.0M$300.0M$400.0M2019: $67.5M$67.5M20192020: $291.2M$291.2M2020+331%2021: $297.4M$297.4M2021+2%2022: $329.9M$329.9M2022+11%2023: -$22.4M-$22.4M20232024: $342.4M$342.4M20242025: $336.8M$336.8M2025−2%2026: $309.4M$309.4M2026−8%
Net income10111213147$190.3M in 2026
-$100.0M0$100.0M$200.0M$300.0M2019: -$35.8M-$35.8M20192020: $142.3M$142.3M20202021: $164.7M$164.7M2021+16%2022: $205.4M$205.4M2022+25%2023: -$82.3M-$82.3M20232024: $209.3M$209.3M20242025: $214.6M$214.6M2025+3%2026: $190.3M$190.3M2026−11%

Every line of the income statement as filed: the last 3 fiscal years, latest first.7

Period ending2026-03-312025-03-312024-03-31
Total revenues$1.1B$1.1B$1.1B
Cost of sales excluding depreciation$482.8M$494.4M$492.8M
Cost of sales depreciation$10.3M$8.9M$8.1M
Cost of sales$493.1M$503.3M$500.9M
Gross profit$595.6M$634.5M$624.4M
Advertising and marketing$148.8M$155.7M$153.3M
General and administrative$116.4M$108.2M$106.2M
Depreciation and amortization$20.9M$21.3M$22.6M
Goodwill and tradename impairment$0$12.5M$0
Total operating expenses$286.2M$297.7M$282.0M
Operating income$309.4M$336.8M$342.4M
Interest expense, net$42.3M$47.6M$67.2M
Other expense (income), net$9.6M$5.0M-$756.0K
Total other expense, net$51.9M$52.6M$66.4M
Income before income taxes$257.5M$284.2M$276.0M
Provision for income taxes$67.2M$69.6M$66.7M
Net income$190.3M$214.6M$209.3M
Basic (in USD per share)$3.93$4.32$4.21
Diluted (in USD per share)$3.91$4.29$4.17
Basic (in shares)48.5M shares49.7M shares49.8M shares
Diluted (in shares)48.7M shares50.1M shares50.2M shares
Currency translation adjustments$9.4M-$3.1M-$2.9M
Unrecognized net (loss) gain on pension plans-$96.0K-$81.0K$9.0K
Total other comprehensive income (loss)$9.3M-$3.2M-$2.9M
Comprehensive income$199.6M$211.4M$206.4M

Compare Prestige Brands with another company

Corporate structure

Prestige Brands sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Prestige Brands

  • Prestige Brands Tarrytown, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

The story

Prestige Brands Holdings, Inc. was established in 1999 to acquire, revitalize, and line extend leading, often neglected but healthy brands that were considered non-core at major consumer products companies. In 2004, MidOcean Partners sold Prestige Brands to GTCR Golder Rauner.

Acquisitions

The company acquired Blacksmith Brands' portfolio of five brands in 2010.

In December 2011, the company agreed to purchase 17 brands from GlaxoSmithKline including BC Powder, Beano, Ecotrin, Fiber Choice, Goody's Powder, Sominex and Tagamet for $660 million.

In 2013, Prestige Brands Holdings, Inc. acquired Care Pharmaceuticals of Bondi Junction, New South Wales, Australia, a privately held marketer and distributor of over-the-counter (OTC) healthcare brands for children and adults.

In 2014, the company purchased Hydralyte in Australia and New Zealand from the Hydration Pharmaceuticals Trust of Victoria, Australia. Hydralyte is the leading oral rehydration product in Australia and New Zealand.

In April 2014, Prestige Brands Holdings, Inc. announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other over-the-counter healthcare products, for $750 million in cash.

In November 2015, Prestige Brands Holdings, Inc. announced that it has entered into a definitive agreement to acquire DenTek Oral Care Inc. (DenTek), a privately held marketer and distributor of oral care products for $225 million in cash.

In December 2016, Prestige Brands Holdings, Inc. agreed to buy C.B. Fleet Co. from private-equity firm Gryphon Investors for about $825 million.

Read the full text

In July 2021, consumer health business assets were acquired from Akorn Operating Company, LLC for $228.9 million adding TheraTears and other products to their brands.

Divestitures

In 2009, Prestige sold its Denorex and Prell brands of shampoo. It has since divested Fiber Choice, PediaCare, New-Skin, and Dermoplast (2016).

In 2018, Prestige sold off their household cleaning supply division.

From Wikipedia’s article on Prestige Consumer Healthcare, shared under CC BY-SA 4.0.8

Leadership

Who has led Prestige Brands, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Frank Palantoni2006
  2. Mark Pettie2007–2009
  3. Matthew Mannelly2009–2015
  4. Charles Hinkaty2011
  5. Ronald M. Lombardi2016–now

Chair

  1. Mark Pettie2007–2009

President

  1. Frank Palantoni2006
  2. Matthew Mannelly2009–2015
  3. Charles Hinkaty2011

Chief financial officer

  1. Ronald M. Lombardi2010–2015
  2. David S. Marberger2015–2016
  3. Christine Sacco2016–now

Chief operating officer

  1. Frank Palantoni2006
  2. Christine Sacco2025–now
200020052010201520202025
Board members and other officers (41)

Products and brands

Prestige Consumer Healthcare owns many over-the counter medicines and products, including:

From Wikipedia’s article on Prestige Consumer Healthcare, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Blacksmith Brands, Inc. Delaware9
  • Briemar Nominees Pty Ltd. Australia9
  • C.B. Fleet Company, Incorporated Virginia9
  • C.B. Fleet International LLC (formerly C.B. Fleet, International, Inc.) Virginia9
  • C.B. Fleet International(s) Pte. Ltd Singapore9
  • C.B. Fleet Investment Corporation Delaware9
  • Care Acquisition Company Pty Limited Australia9
  • Care Pharmaceuticals Pty Limited Australia9
  • Cellegy Australia Pty Australia9
  • Clear Eyes Pharma Limited England and Wales9
  • DenTek Holdings, Inc. Delaware9
  • DenTek Oral Care Limited England and Wales9
  • DenTek Oral Care, Inc. Tennessee9
  • Insight Pharmaceuticals Corporation Delaware9
  • Insight Pharmaceuticals LLC Delaware9
  • Medtech Holdings, Inc. Delaware9
  • Medtech Online Inc. Delaware9
  • Medtech Personal Products Corporation Delaware9
  • Medtech Products Inc. Delaware9
  • PBH Australia Holdings Company Pty Limited Australia9
  • Pakaging Innovations Pty Ltd. Australia9
  • Peaks HBC Company, Inc. Virginia9
  • Pillar5Pharma Inc. Canada9
  • Practical Health Products, Inc Delaware9
All 33 listed subsidiaries
  • Prestige Brands (UK) Limited England and Wales9
  • Prestige Brands Gmbh Germany9
  • Prestige Brands Holdings, Inc. Virginia9
  • Prestige Brands International, Inc. Virginia9
  • Prestige Brands SPE Lender, LLC Delaware9
  • Prestige Brands, Inc. Delaware9
  • Prestige Services Corp. Delaware9
  • The Spic and Span Company Delaware9
  • Wartner USA B.V. Netherlands9

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 14, 20268-K Executive or director change68
  2. Aug 6, 20268-K Results of operations; Regulation FD disclosure69
  3. Jul 15, 20268-K Entered a material agreement; New debt or obligation70
  4. Jul 9, 20268-K Financial statements and exhibits71
  5. Jul 6, 20268-K Entered a material agreement; New debt or obligation; Regulation FD disclosure72
  6. Jun 30, 20268-K Financial statements and exhibits73
  7. Jun 16, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation74
  8. May 13, 20268-K Entered a material agreement; Results of operations; Regulation FD disclosure75
  9. Mar 20, 20268-K Entered a material agreement; Regulation FD disclosure; Other events76
  10. Feb 5, 20268-K Results of operations; Regulation FD disclosure77
  11. Nov 6, 20258-K Results of operations; Regulation FD disclosure78
  12. Aug 7, 20258-K Entered a material agreement; Results of operations; Regulation FD disclosure79
  13. May 11, 2016New chief executive Ronald M. Lombardi becomes CEO19
  14. Aug 22, 2011New chief executive Charles Hinkaty becomes CEO20
  15. Sep 4, 2009New chief executive Matthew Mannelly becomes CEO21
  16. Jan 19, 2007New chief executive Mark Pettie becomes CEO22
  17. May 23, 2006New chief executive Frank Palantoni becomes CEO23
  18. 1996Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.07 a share, on Nov 6, 2025.80

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results69
  2. May 13, 2026Reported quarterly or annual results75
  3. Feb 5, 2026Reported quarterly or annual results77
  4. Nov 6, 2025Reported quarterly or annual results78
  5. Aug 7, 2025Reported quarterly or annual results79
  6. May 8, 2025Reported quarterly or annual results81
  7. Feb 6, 2025Reported quarterly or annual results82
  8. Nov 7, 2024Reported quarterly or annual results83

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

275 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 30 major events, 160 insider forms, 23 large holders, 42 other. The latest 20:

  1. Aug 14, 20268-K EDGAR
  2. Aug 6, 202610-Q EDGAR
  3. Aug 6, 20268-K EDGAR
  4. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  5. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  6. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  7. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jul 15, 20268-K EDGAR
  10. Jul 9, 20268-K/A EDGAR
  11. Jul 7, 2026SCHEDULE 13G/A EDGAR
  12. Jul 6, 20268-K EDGAR
  13. Jun 30, 20268-K/A EDGAR
  14. Jun 29, 2026ARS ANNUAL REPORT TO SECURITY HOLDERS EDGAR
  15. Jun 29, 2026DEF 14A EDGAR
  16. Jun 16, 20268-K EDGAR
  17. May 14, 202610-K EDGAR
  18. May 14, 20264/A OWNERSHIP DOCUMENT EDGAR
  19. May 13, 20268-K EDGAR
  20. May 12, 20264 OWNERSHIP DOCUMENT EDGAR

The 275 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.7,831,333$370.2M0.0%+442,843
Ariel Investments, LLC4,868,711$230.1M2.3%+594,385
Vanguard Portfolio Management LLC2,825,340$133.6M0.0%+21,512
Dimensional Fund Advisors LP2,661,291$125.8M0.0%−11,486
Fuller & Thaler Asset Management, Inc.2,331,821$110.2M0.3%New
Vanguard Capital Management LLC2,136,944$101.0M0.0%+43,951
State Street Corp2,116,513$100.0M0.0%+145,532
Brandes Investment Partners, LP2,051,060$97.0M0.7%+1,196,941
Kayne Anderson Rudnick Investment Management LLC1,872,023$88.5M0.3%−330,583
Geode Capital Management, LLC1,571,742$74.3M0.0%+111,707
Allspring Global Investments Holdings, LLC1,271,950$61.3M0.1%−286,154
Morgan Stanley1,243,931$58.8M0.0%−113,539
Nordea Investment Management Ab828,628$39.3M0.0%+229,253
Northern Trust Corp773,449$36.6M0.0%+23,144
Westwood Holdings Group Inc750,445$35.5M0.3%−369,270
Rice Hall James & Associates, LLC689,692$32.6M1.6%+168,070
Manufacturers Life Insurance Company, The658,659$31.1M0.0%+185,508
Charles Schwab Investment Management Inc654,174$30.9M0.0%−87,975
UBS Group AG638,605$30.2M0.0%+246,396
Massachusetts Financial Services Co /ma/629,836$29.8M0.0%+31,810
Boston Trust Walden Corp609,949$28.8M0.2%−33,391
Goldman Sachs Group Inc586,536$27.7M0.0%+128,918
Citadel Advisors LLC564,157$26.7M0.0%+380,717
Bank Of America Corp /de/555,894$26.3M0.0%+8,452
Raymond James Financial Inc464,353$21.9M0.0%−92,107

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Prestige Brands is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPrestige Brands, Inc.2
  • CIK0001293894
  • Employer ID (EIN)80-00917502
  • Incorporated inDelaware2
  • Fiscal year endsMarch 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address90 North Broadway, Irvington, NY 105332
  • Phone(914) 524-68102
  • On EDGAR sinceJul 6, 20042
  • Filings27 in all: S-4/A (8), 424B3 (4), CORRESP (4), S-4 (4), EFFECT (3), UPLOAD (3), S-1 (1)2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinancePBH quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90